MX350126B - Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. - Google Patents

Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.

Info

Publication number
MX350126B
MX350126B MX2014002595A MX2014002595A MX350126B MX 350126 B MX350126 B MX 350126B MX 2014002595 A MX2014002595 A MX 2014002595A MX 2014002595 A MX2014002595 A MX 2014002595A MX 350126 B MX350126 B MX 350126B
Authority
MX
Mexico
Prior art keywords
toxin
difficile
tab
proteins
isolated polypeptide
Prior art date
Application number
MX2014002595A
Other languages
English (en)
Other versions
MX2014002595A (es
Inventor
Larry Ellingsworth
Steven Fuhrmann
Stahl Stefanie Kluepfel
Gregory Glenn
Kerstin Westritschnig
David Flyer
jing hui Tian
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350126(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of MX2014002595A publication Critical patent/MX2014002595A/es
Publication of MX350126B publication Critical patent/MX350126B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a polipéptidos aislados C-TAB.G5 y C-TAB.G5.1 que comprenden los dominios de unión al receptor de la toxina A y la toxina B de C. difficile, tal como se define en las secuencias de aminoácido de la SEQ ID NO: 2 y la SEQ ID NO: 4; los polipéptidos aislados C-TAB.G5 y C-TAB.G5.1 se pueden usar para neutralizar los efectos tóxicos de la toxina A y/o la toxina B de C. difficile.
MX2014002595A 2010-09-03 2011-09-05 Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. MX350126B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37989210P 2010-09-03 2010-09-03
PCT/EP2011/065304 WO2012028741A1 (en) 2010-09-03 2011-09-05 Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Publications (2)

Publication Number Publication Date
MX2014002595A MX2014002595A (es) 2014-10-13
MX350126B true MX350126B (es) 2017-08-28

Family

ID=44799993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002595A MX350126B (es) 2010-09-03 2011-09-05 Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.

Country Status (22)

Country Link
US (7) US9598472B2 (es)
EP (3) EP3895728A1 (es)
JP (1) JP6121421B2 (es)
KR (1) KR101907434B1 (es)
CN (1) CN103957931B (es)
AU (1) AU2011298306B2 (es)
BR (1) BR112014004896B1 (es)
CA (1) CA2873272C (es)
CY (1) CY1118664T1 (es)
DK (1) DK2753352T4 (es)
ES (2) ES2867375T3 (es)
HR (1) HRP20170193T4 (es)
HU (1) HUE033342T2 (es)
LT (1) LT2753352T (es)
MX (1) MX350126B (es)
PL (1) PL2753352T5 (es)
PT (1) PT2753352T (es)
RS (1) RS55707B2 (es)
SI (1) SI2753352T2 (es)
SM (1) SMT201700124T1 (es)
WO (1) WO2012028741A1 (es)
ZA (1) ZA201400610B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
CN103619871B (zh) 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
AU2016203241B2 (en) * 2011-05-27 2018-05-10 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN107098977A (zh) 2011-05-27 2017-08-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
KR20140101835A (ko) 2011-12-08 2014-08-20 노파르티스 아게 클로스트리듐 디피실레 톡신-기반 백신
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
ES2939307T3 (es) 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa Composición inmunogénica
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
US10533036B2 (en) * 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
EP3433264A4 (en) * 2016-03-21 2019-08-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING
ES2957939T3 (es) 2017-04-13 2024-01-30 Valneva Austria Gmbh Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos
BR112020024514A2 (pt) 2018-06-19 2021-03-02 Glaxosmithkline Biologicals S.A. composição imunogênica
WO2020173928A1 (en) * 2019-02-25 2020-09-03 Previpharma Consulting Gmbh Epitopes of clostridium difficile toxins a and b and uses thereof
CN115698044A (zh) 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AU709586B2 (en) * 1994-10-24 1999-09-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
JP2001501930A (ja) 1996-10-04 2001-02-13 オークランド ユニサーヴィスィズ リミテッド 神経酵素の調節
WO1998029134A2 (en) 1996-12-31 1998-07-09 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP4188092B2 (ja) 2001-05-21 2008-11-26 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシ核酸分子
WO2003047602A1 (en) 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
NZ548821A (en) * 2004-02-06 2009-12-24 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
DE202005021414U1 (de) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
EP2167119B1 (en) * 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
AU2008299885C1 (en) 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
MX339253B (es) * 2010-04-15 2016-05-18 Progenics Pharm Inc Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
CN103619871B (zh) * 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
CN107098977A (zh) 2011-05-27 2017-08-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
ES2939307T3 (es) * 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa Composición inmunogénica
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

Also Published As

Publication number Publication date
CY1118664T1 (el) 2017-07-12
US20210393761A1 (en) 2021-12-23
EP2753352A1 (en) 2014-07-16
ES2867375T3 (es) 2021-10-20
WO2012028741A1 (en) 2012-03-08
BR112014004896A2 (pt) 2021-01-26
CN103957931B (zh) 2017-10-24
ZA201400610B (en) 2015-09-30
US20170239340A1 (en) 2017-08-24
JP2014525249A (ja) 2014-09-29
MX2014002595A (es) 2014-10-13
US11357844B2 (en) 2022-06-14
PL2753352T3 (pl) 2017-07-31
KR20140057315A (ko) 2014-05-12
RS55707B2 (sr) 2022-10-31
AU2011298306B2 (en) 2017-10-19
DK2753352T3 (da) 2017-03-06
CA2873272C (en) 2020-10-27
US20150056238A1 (en) 2015-02-26
EP3167899B1 (en) 2021-03-24
SI2753352T2 (sl) 2022-10-28
HRP20170193T1 (hr) 2017-06-02
LT2753352T (lt) 2017-05-25
PT2753352T (pt) 2017-03-08
KR101907434B1 (ko) 2018-10-12
DK2753352T5 (da) 2017-05-01
US20250360191A1 (en) 2025-11-27
ES2631032T5 (es) 2022-10-26
SI2753352T1 (sl) 2017-06-30
BR112014004896B1 (pt) 2023-02-14
US20210121554A1 (en) 2021-04-29
US12324831B2 (en) 2025-06-10
CA2873272A1 (en) 2012-03-08
US10357557B2 (en) 2019-07-23
EP2753352B1 (en) 2017-01-25
AU2011298306A1 (en) 2014-02-20
CN103957931A (zh) 2014-07-30
US20190290747A1 (en) 2019-09-26
EP2753352B2 (en) 2022-08-10
JP6121421B2 (ja) 2017-04-26
PL2753352T5 (pl) 2022-10-17
US20230173052A1 (en) 2023-06-08
ES2631032T3 (es) 2017-08-25
DK2753352T4 (da) 2022-09-12
RS55707B1 (sr) 2017-07-31
US9598472B2 (en) 2017-03-21
SMT201700124T1 (it) 2017-05-08
HK1200357A1 (en) 2015-08-07
HUE033342T2 (en) 2017-11-28
HRP20170193T4 (hr) 2022-09-02
US10821166B2 (en) 2020-11-03
US11478540B2 (en) 2022-10-25
EP3167899A1 (en) 2017-05-17
EP3895728A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
MX350126B (es) Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
NZ600732A (en) Oxyntomodulin peptide analogue
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
PH12018501250A1 (en) Chimeric factor viii polypeptides and uses thereof
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ625630A (en) Human il-23 antigen binding proteins
NZ616989A (en) Therapeutic nuclease compositions and methods
NZ600731A (en) Oxyntomodulin peptide analogue
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
MY182429A (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
NZ612161A (en) Radiolabled her2 binding peptides
NZ601591A (en) Methods for treating pancreatic cancer
IN2014KN01713A (es)
IN2014KN01716A (es)
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2012051498A3 (en) Antibodies that bind amyloid oligomers
NZ706884A (en) Fc gamma receptor iib variants
MX2015003310A (es) Moleculas de union il-17a novedosas y usos medicos de las mismas.
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
GB201110815D0 (en) Incorporation of subtituted lysines into polypeptides

Legal Events

Date Code Title Description
FG Grant or registration